Chesapeake IRB Announces Acquisition of Institutional Biosafety Corporation
Columbia, Md., June 6, 2017 (Business Wire) – Chesapeake IRB, the technology-enabled independent institutional review board (IRB) serving the clinical research industry, announced it has acquired Institutional Biosafety Corporation (IBC), a provider of institutional biosafety committee services located in Rockville, Md.
The acquisition of IBC expands Chesapeake’s services with the capability to provide comprehensive review and oversight of research utilizing recombinant or synthetic DNA molecules, including clinical trials involving genetic engineering and gene therapy.
“We are excited to partner with IBC to offer comprehensive biosafety support services that will further serve our customers conducting biological and biomedical clinical research trials,” said Jeff Wendel, president and CEO of Chesapeake. “Together with our market-leading IRB services, we now offer customers the ability to properly assess the biosafety precautions essential for mitigating risks to researchers and patients.”
“By utilizing the exceptional Chesapeake platform, Chesapeake’s IRB review process and IBC’s institutional biosafety committee services, we can offer the speed, efficiency and quality customers need to grow their research capacity and safeguard research participants,” said Gil Price, co-founder and CEO of Institutional Biosafety Corporation.
Federal regulations require institutions to have institutional biosafety committee oversight if they are conducting research involving recombinant or synthetic nucleic acid molecules (r/sNA) and are funded by the National Institutes of Health or taking place at sites that receive NIH funding. Many privately sponsored studies voluntarily utilize institutional biosafety committee services due to their interest in seeking NIH funding, other third-party regulatory requirements, or for enhanced research safety oversight.
About Chesapeake IRB
Chesapeake IRB, an AAHRPP-accredited company, provides independent IRB submission and review services to pharmaceutical, biotech, and medical device companies, as well as academic medical centers and hospital systems. Its paperless, cloud-based submission and review platform, CIRBI, leads the field and has set the standard in review turnaround time, quality, and document accessibility. Headquartered in Columbia, MD, Chesapeake IRB has offices across the United States and a wholly owned subsidiary, IRB Services, with offices in Toronto and Montreal, Canada. Visit chesapeakeirb.com for more information.
Empowering Sites and Patients: The Impact of Personalized Support in Clinical Trials
November 26th 2024To meet the growing demands of clinical research, sponsors must prioritize comprehensive support models, such as clinical site ambassadors and patient journey coordinators, who can address operational challenges and improve site relationships, patient satisfaction, and overall trial efficiency.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
FDA Finalizes Decentralized Clinical Trial Guidance
November 25th 2024The FDA's guidance is part of a broader effort to modernize clinical trials, improve efficiency, reduce participant burden, and expand access, particularly for underrepresented populations and those in geographically or economically constrained areas.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
